Circulating GLP-1 Levels in Patients with Pheochromocytoma/Paraganglioma
Table 1
Clinical characteristics of patients with PPGL (n = 30).
Characteristics
Age (years)
40.4 ± 14.5
Female, n (%)
17 (56.7%)
Body mass index (kg/m2)
21.54 ± 3.42
Waist circumference (cm)
80.88 ± 10.52
PCC unilateral, n (%)
21(91.3%)
PCC bilateral, n (%)
2 (8.7%)
Extra-adrenal (PGL), n (%)
7 (23.3%)
Tumor diameter (cm)
4.0 (3.4–5.5)
Asymptomatic, n (%)
5 (16.7%)
Symptomatic, n (%)
25 (83.3%)
Headache, n (%)
15 (50%)
Palpitations, n (%)
14 (46.7%)
Persistent hypertension, n (%)
16 (53.3%)
Beta-blockers, n (%)
18 (60%)
Alpha-blockers, n (%)
29 (96.7%)
Hyperglycemia, n (%)
16 (53.3%)
Dyslipidemia, n (%)
9 (30%)
Fasting plasma glucose (mmol/L)
6.1 (4.9–6.6)
Fasting plasma total GLP-1 (pmol/L)
27.8 ± 14.7
DPP-IV inhibitors or GLP-1 agonists, n (%)
0
Insulin therapy, n (%)
7 (23.3%)
Triglyceride (mmol/L)
1.31 ± 0.67
LDL-C (mmol/L)
3.17 ± 0.79
HDL-C (mmol/L)
1.37 ± 0.32
Serum creatinine (umol/L)
66.5 (56.0–74.3)
Plasma metanephrine (nmol/L)
1.09 (0.21–3.66)
Plasma normetanephrine (nmol/L)
9.11 (4.23–20.56)
Data are expressed as mean ± SD or median (internal quartile range (IQR)). PPGL: pheochromocytoma and paraganglioma; PCC: pheochromocytoma; PGL, paraganglioma; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; GLP-1, glucagon-likepeptide-1.
